GBX International Group Inc (GBXI) Releases its CSi-Cancer Killing 3rd Party Independent Drug Valuation(s) - December 13, 2023

The GBXI Conglomerate has been compelled to release to the public its Capizate Independent 3rd Party Cancer Drug Valuation(s), a complete insight of the Company Profile(s), Cancer Drug Valuation(s) and overall Company Strengths and Areas of Improvements.

(Please click the link below or the BREAKING NEWS image on the TOP LEFT Side bar to view the FULL Capizate 3rd Party Independent Valuation Report)

https://americanstatesuniversity.com/images/Cancer_Drug_Valuation_Full_Report_GBXI-CSi_11_2023.pdf?_t=1702506082

*** This Valuation Report is a pre-release to the commencement of the Company liquid share trading to CONFIRM overall Shareholder Confidence answering questions and Strategically Counter any adverse communications of the REAL VALUE to the Company for each of its Cancer Killing Drugs.

As well, it provides a clear assessment of a New Starting Point for its Market Trading Values and the Reality of moving out of its current exchange non-trading status into a liquid market trading status by utilizing its assets to form a base of Financial Valuation Successful Reporting and its Successful Operational Advancements over the years.
 
*** GBXI Conglomerate Drug Valuation Highlights:

This is a verified 3rd Party Asset Valuation Report (Situation Analysis) prepared by the experts at Capizate. There was no input from the Company or its Executives regarding the dollar values stated, except to the extent of providing the listed documents for the valuation process outlined in the Capizate Valuation Report.

Today’s Current Cancer Drug Valuation (1) Drug:

$26,763,459.00 USD – Weighted (Pre-Money)
$21,410,767.00 USD – Low Range (Pre-Money)
$32,116,150.00 USD – High Range (Pre-Money)
 
Today, Pre-Money, (1) Drug Valuation:           $26,763,459.00 USD

$1.5 million, Post-Money, (1) Drug Value:     $29,263,459.00 USD
 
Cancer Drug comparables same space and same stage of development.
        
(9) compared: $53.999.500.00 USD average value(s)

Our Score: 623 out of 1,000
Target Score 925 out of 1,000

An immediate increased Score brings our (1) Drug Valuation to that level.
 
Cannabis Science developed endorsements, collaborations, agreements, and formal strategic partnerships stemming from 2017-2019 with Harvard University and other prominent organizations for the development of a series of cancer treatments.
 
Cannabis Science is raising $2.5 Million ($1.5 Million immediate and $1 Million follow on) to complete clinical trials of its cancer treatment cannabinoids. The company has other assets and subsidiary companies that are nonoperational, but have promise, such as the American States University.
 
The Company’s acquiring entity is a Nevada entity that has been confirmed as current and properly filed as of June 30, 2023 (GBXI) GBX INTERNATIONAL GROUP, INC. Entity Number: C13020- 1997; Status: Active; Formation Date: 06/19/1997 NV Business ID: NV19971199937.
 
GBXI Corporate Filings, Financials, and trading status has been delayed due to change of control filings and approvals. The Company has several options on the list for trading resumption as it pursues its regulatory approvals. The Company is pursuing the fastest path to trading first and will proceed down the list as it moves towards its ultimate goal of bringing all the GBXI conglomerate company shares back trading again.
 
In closing we Wish all our Shareholders a Happy Holiday Season as we Push Forward to bring our shares back trading asap. This 3rd party independent report from Capizate is key, evidencing the Truth of our Success Killing Cancers and the Asset Values we have built from Successfully doing so.

We continue to build more assets values for ALL our Shareholders to participate and enjoy their returns on their investments, regardless of the hurdles we have been through and/or negative feedback from the general public and/or any entity engaged in competition to our Successful resumption of trading (Our Ultimate Short-term Goal).
 
All the Best Guys!
Talk soon and Thanks for your continued Support!
Raymond - IGWT

Mr. Raymond C. Dabney
President & CEO, Chancellor
GBX International Group Inc., OTC: GBXI
American States University
Cannabis Science Inc.

raymond.dabney@americanstatesuniversity.com

Cell +1.778.288.1389

https://www.cannabisscience.com/
https://www.americanstatesuniversity.com/

(Please click the link below or the BREAKING NEWS image on the TOP LEFT Side bar to view the FULL Capizate 3rd Party Independent Valuation Report)

https://americanstatesuniversity.com/images/Cancer_Drug_Valuation_Full_Report_GBXI-CSi_11_2023.pdf?_t=1702506082

GBX International Group Inc (GBXI) Releases its CSi-Cancer Killing 3rd Party Independent Drug Valuation(s) - December 13, 2023

The GBXI Conglomerate... Show more

Jon Morse, Raymond C. Dabney and 2 others

Raymond C. Dabney We will remain Calm, Cool, Collected and Thank God as we enter the Holiday Season and "Rise up" to "Claim our Success" for ALL our Shareholders!... Show more

1 year ago

•••

Tim Hofman We need a jumping for joy emoji! Awesome sauce! 1 year ago

•••

Raymond C. Dabney Or getting up off the floor from the initial shock after Realizing what we have Actually created over the Years for our Success !!! 1 year ago

•••

American States University

*** Warning this document contains graphic images.

Click the Below Image to Review our Cancer Drug Comparables

1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:

*** Please click image below.

2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:

*** Please click image below.

*** PLUS

(3) other Cannabis Science
REAL WORLD Successes:

Stage 4 Breast Cancer

Skin Cancer

Karposis Sarcoma

The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.

Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.

We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.

Click here to review the Report:

Case No. 2:17-CV-02271-KJM-JDP

Inspire, Dream, Change

YOUR DIGITAL ERA Personal & Business Access Learning HUB

Photos

Observational Studies

CSi-VIP & CBIS-Shareholder Legacy

Click the ABOVE Image to Review our 1-Million Strong FC, Media Kit

*** Warning this document contains exciting images.

Please Click the above image for information to become a CSi-VIP & CSi-VIP Legacy Cancer Drug Owner

Pease Click the Calendar image to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".

Click the above Image to become one of the First 1-Million Strong Killing Cancers, Fight Club Members to help 'Make that Change' Join in Now! * Warning this Membership contains Exciting Results.

PS ...** ALL of our CSi-VIP's and those who Donated through the ASU/CSi-EDP GO-Fund-Me Promotion you do not need to purchase anything, you are ALREADY included in the "First" 1-Million Membership Club, CONGRATULATIONS !!!

Cannabis Science CEO, Presents …

The FINAL “CBIS GIFT Shares” Issuances!

DECEMBER 2024, Cheers! & HAPPY HOLIDAYS !!!

ALL GIFT Shares 1, 2, & 3 being ISSUED !!!

LAST Steps:

Please confirm Yours NOW !!!

1. CONFIRM Correct Total Share Amount(s)

2. CONFIRM Correct Name(s) on CERTIFICATE

3. CONFIRM Correct Mailing Address

*** giftshares@icannabinoid.com

ASU/CSi-EDP-ECO-System
At it's FINEST !!!

WHICH ONE ARE YOU ??

Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???

We can make this HAPPEN way FASTER Working as a TEAM !!!

WHAT Matters is how much you CARE about KILLING CANCERS ...

This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.

2025 Audit considerations NASDAQ.

Cannabis Science Inc.
Share Structure 2025

Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.

Common Stock:
Authorized:
5,000,000,000

Issued:
2,839,095,296

Fully Diluted:
4,510,547,648

Class A Common Stock
Authorized:
100,000,000

Issued:
0

Class B Common Stock
Authorized:
1,500,000,000

Issued:
0

Preferred Stock
Authorized:
1,000,000

Issued:
1,000,000

Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.

You already know our Extensive LIST of GROUNDBREAKING Products.

1-Million STRONG TV Coverage, HARVARD Award Success.

TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE

*** APPLY for FREE in CONFIDENCE and Success.

Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.

EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!

Activity Stream

GBX International Group Inc (GBXI) Releases its CSi-Cancer Killing 3rd Party Independent Drug Valuation(s) - December 13, 2023

(Please click the link below or the BREAKING NEWS image on the TOP LEFT Side bar to view the FULL Capizate 3rd Party Independent Valuation Report)

https://americanstatesuniversity.com/images/Cancer_Drug_Valuation_Full_Report_GBXI-CSi_11_2023.pdf?_t=1702506082

Today’s Current Cancer Drug Valuation (1) Drug:

$1.5 million, Post-Money, (1) Drug Value:     $29,263,459.00 USD
 
Cancer Drug comparables same space and same stage of development.
        
(9) compared: $53.999.500.00 USD average value(s)

Our Score: 623 out of 1,000
Target Score 925 out of 1,000

Mr. Raymond C. Dabney
President & CEO, Chancellor
GBX International Group Inc., OTC: GBXI
American States University
Cannabis Science Inc.

raymond.dabney@americanstatesuniversity.com

Cell +1.778.288.1389

https://www.cannabisscience.com/
https://www.americanstatesuniversity.com/

(Please click the link below or the BREAKING NEWS image on the TOP LEFT Side bar to view the FULL Capizate 3rd Party Independent Valuation Report)

https://americanstatesuniversity.com/images/Cancer_Drug_Valuation_Full_Report_GBXI-CSi_11_2023.pdf?_t=1702506082

GBX International Group Inc (GBXI) Releases its CSi-Cancer Killing 3rd Party Independent Drug Valuation(s) - December 13, 2023

The GBXI Conglomerate... Show more

Jon Morse, Raymond C. Dabney and 2 others

Raymond C. Dabney We will remain Calm, Cool, Collected and Thank God as we enter the Holiday Season and "Rise up" to "Claim our Success" for ALL our Shareholders!... Show more

1 year ago

•••

Tim Hofman We need a jumping for joy emoji! Awesome sauce! 1 year ago

•••

Raymond C. Dabney Or getting up off the floor from the initial shock after Realizing what we have Actually created over the Years for our Success !!! 1 year ago

•••